LONG-TERM BIOLOGICAL TREATMENT IN LARGE VESSELS VASCULITIS: A RETROSPECTIVE SINGLE-CENTER STUDY ON 30 PATIENTS FROM 2011 TO 2018

Francesca Regola1, Giovanni Bosio2, Elisabetta Cerudefi, Angela Tincani4, Paola Toniati1, 1U.O. Rheumatology and Clinical Immunology, ASST Spedali Civili of Brescia, Department of Clinical and Experimental Sciences, Brescia, Italy; 2Department of Nuclear Medicine, Spedali Civili of Brescia, Brescia, Italy

Background: Glucocorticoids (GC) are the mainstay in the treatment of large vessels vasculitis (LVV), while conventional immunosuppressants have modest GC-sparing effect. Recent studies show that biological drugs could represent a valid therapeutic option, especially in patients with severe or relapsing LVV. Their role in the treatment of LVV is expanding, but only few data are available on their long-term efficacy and safety [1,2].

Objectives: Our aim is to describe the 8 years’ experience of a single Italian center in biological treatment of patients with large vessels vasculitis (LVV).

Methods: We collected retrospectively clinical data from 30 patients affected by LVV and treated with biological drugs. Data from 19F-FDG PET and CT or MRI associated with improvement of clinical and inflammatory index (ESR and CRP) were used as criteria of response to treatment.

Results: Between 2011 and 2018 we treated 30 LVV patients (22 women and 8 men) with biological drugs: 10 patients with Takayasu arteritis (TAK), 17 patients with large-vessel giant cell arteritis (LV-GCA) and 3 patients with aortitis. The median age (10th–90th percentile) at the diagnosis was 63 (21–79) years. Biological treatment was started right after the diagnosis in 15 patients, while 15 patients had a long-standing relapsed disease (time between diagnosis and biological therapy 6 (1–43) months). The mean follow-up time of patients was 26 (4–72) months.

Anti-TNF-α drugs (infliximab, adalimumab, golimumab) were used in 9 patients; while anti-IL-6R (tocilizumab) was used in 30 patients. During the follow up, 9 patients (23%) switched to another biologic for relapse of the disease or for infusion adverse reactions; in 3 cases multiple switches were made.

Infliximab (IFX) was used in 7 patients for a median period of 12 (3–33) months: 3 patients achieved stable remission, 3 had an infusion adverse reaction, 1 had a relapse of the disease after 60 months of therapy, Adalimumab (ADA) was used in 3 patients and then suspended in all of them for relapse of the disease after 3, 12 and 93 months of therapy, respectively. Golimumab was used in 2 patients: one suspended therapy for developing follicular thyroid cancer, one switched to another biologic for persistent active disease.

Tocilizumab (TOCZ) was used in all 30 patients for a median period of 20 (4–54) months: in 25 cases it was the first line therapy, in the other 5 cases it was used after an anti-TNF-α drug. 25 patients out of 30 (84%) achieved stable remission and in 6 of them a dose tapering was possible, with no sign of relapse.

Three patients in TCZ had an adverse reaction; one developed a uveitis and one had a relapse of TAK.

In our last examination 29 out of 30 patients in biological therapy demonstrated a good control of the disease with clinical improvement, also confirmed by PET, TC and/or MRI, and reduction of inflammatory index (ESR and CRP), compared to before starting treatment. Biologics also demonstrated an important steroid sparing effect; mean prednisone dose at the beginning of treatment was 25 mg/day (12–50), while at the last follow-up was 6 mg/day (1–15) (p<0.0001; Wilcoxon test).

Conclusion: In our cohort of 30 patients biological treatments demonstrated long-term efficacy and acceptable safety profile and important steroid sparing effect.

REFERENCES

Disclosure of Interests: Francesca Regola: None declared, Giovanni Bosio: None declared, Elisabetta Cerudefi: None declared, Angela Tincani Consultant for: UCB, Pfizer, Abbvie, BMS, Sanofi, Roche, GSK, Alpha-Sigma, Lilly, Janssen, Cellgene, Novartis, Paola Toniati: None declared


SELF-MANAGEMENT BEHAVIOURS IN ANCA-ASSOCIATED VASCULITIS: SECONDARY ANALYSIS OF INTERVIEW DATA

Tim Reynolds1, Emma Dures2, Sue Ashdown3, Peter Cronholm4, Raashid Luqmani5, Peter Merke6, Nataliya Milman7, Jacqueline Peck8, Joanna Robson2, 1University Hospitals Bristol NHS Foundation Trust, Bristol, United Kingdom; 2University of the West of England, Bristol, United Kingdom; 3Patient partner, Oxford, United Kingdom; 4University of Pennsylvania Perelman School of Medicine, Philadelphia, United States of America; 5University of Oxford, Oxford, United Kingdom; 6University of Pennsylvania, Philadelphia, United States of America; 7Division of Rheumatology, Department of Medicine in Ottawa, Ottawa, Canada

Background: ANCA-associated vasculitis (AAV) is a significant cause of morbidity and mortality. Meeting the challenges of AAV effectively requires patients to engage in self-management, including medical management, role management, and emotional management.1 Self-management is recognised as a key aspect of chronic disease management and forms an important part of the National Health Service 5-year forward plan and the UK strategy for rare diseases.2 Nonetheless, there has been limited specific research into the role of self-management in the AAV literature.

Objectives: To explore experiences and views of self-management amongst AAV patients.

Methods: A secondary analysis of all interview transcripts from a previous project exploring health-related quality of life in relation to AAV was performed.3 Deductive analysis was used to map appropriate areas discussed by patients to the self-management framework proposed by Lorig and Holman.4 Inductive analysis was used to identify emergent themes that did not fit into this framework.

Results: Interview data were collected from 50 patients with AAV (25 men), from the UK (n=18), USA (n=17) and Canada (n=15). Diagnoses included GPA (n=26), EGPA (n=17) and MPA (n=7). Thirty-four patients were diagnosed within the last 2 years and 16 were diagnosed more than 2 years ago.4 From the core tasks proposed in Lorig and Holman’s framework, patients with AAV appear to attribute particular importance to maintaining life roles and to a lesser extent medication management and dealing with the emotions of chronic disease. Core skills necessary to self-manage in AAV include learning to take action as part of self-efficacy, forming productive health-care partnerships, learning about decision making (requiring disease and self-awareness), utilising resources effectively, and problem-solving.

Three themes emerged that were not included in Lorig and Holman’s framework that respondents related to self-management abilities including: 1) support received from family, support groups, and religion; 2) the influence of pre-morbid personality factors; 3) the role patients attributed to developing a foundation of specific AAV knowledge in their subsequent ability to self-manage.

Conclusion: Patients with AAV self-manage in a variety of ways and their needs may change over time. Patients may benefit from support to help manage changing life roles and to deal with the challenges of having a chronic disease. Over time, support may need to shift focus onto core skills including recognising when to take action; forming effective partnerships with healthcare providers, family, and friends; adaptations to day-to-day changes in their condition; utilising resources appropriately; and strategies for problem-solving.

REFERENCES

Disclosure of Interests: Tim Reynolds: None declared, Emma Dures Grant/research support from: Has previously received an independent learning grant from Pfizer, however the work has been completed and

Scientific Abstracts